Usage: Imdelltra is indicated for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
Usage: Imfinzi is a PD-L1 blocking antibody indicated for adults with multiple cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma, endometrial cancer, bladder cancer, and gastric or gastroesophageal junction adenocarcinoma.
Usage: Tecentriq is a PD-L1 blocking antibody for treating several cancers in adults: non-small cell and small cell lung cancer, hepatocellular carcinoma, BRAF V600-positive melanoma, alveolar soft part sarcoma (including pediatric patients age 2+), and muscle invasive bladder cancer.
Usage: Zepzelca treats adults with small cell lung cancer: as maintenance therapy (with atezolizumab) for extensive-stage SCLC after first-line induction, and for metastatic SCLC that progressed on or after platinum-based chemotherapy (accelerated approval).